Form 4 for PCVX Vaxcyte, Inc.
Accepted 2026-07-06 18:25:54 ET · period of report 2026-07-01 · accession 0001813798-26-000013 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-07-06 18:25 | 2026-07-01 | PCVX | Wassil Jim | COO | M - OptEx | $5.35 | +516 | 159.0K | +0.3% | +$2,761 |
| DMT | 2026-07-06 18:25 | 2026-07-01 | PCVX | Wassil Jim | COO | S - Sale+OE | $56.33 | -2,250 | 156.8K | -1% | -$126.7K |
| DT | 2026-07-06 18:25 | 2026-07-01 | PCVX | Wassil Jim | COO | M - OptEx | $0.00 | -516 | 71.1K | -0.7% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-01 | M | A | 516 | $5.35 | 159,010 | D | — | — | |
| 2 | Common | Common Stock | 2026-07-01 | S | D | 1,788 | $56.03 | 157,222 | D | — | — | (F1) The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. (F2) The price reported is a weighted-average price. The shares were sold at prices ranging from $55.60 to $56.595. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2026-07-01 | S | D | 456 | $57.47 | 156,766 | D | — | — | (F1) The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. (F3) The price reported is a weighted-average price. The shares were sold at prices ranging from $56.695 to $57.59. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 4 | Common | Common Stock | 2026-07-01 | S | D | 6 | $57.82 | 156,760 | D | — | — | (F1) The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. |
| 5 | Derivative | Stock Option (right to buy) | 2026-07-01 | M | D | 516 | $0.00 | 71,148 | D | $5.35 · — to 2030-04-17 | 516 Common Stock | (F4) Stock Option is fully vested and exercisable. |